Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408518 | 0.79 | GPR55 (0.48) | SMN1; SMN2ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL6765188 | 0.76 | PDE5A (0.40) | PDE5A | |
| SCHEMBL5407863 | 0.66 | F10 (0.44) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL5408430 | 0.64 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4762032 | 0.63 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1PDE5A | |
| SCHEMBL4762020 | 0.62 | PDE5A (0.47) | PDE5A | |
| SCHEMBL5409979 | 0.62 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL16188034 | 0.62 | MEN1 (0.63) | SMN1; SMN2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4762021 | 0.61 | PDE5A (0.40) | PDE5A | |
| SCHEMBL5412985 | 0.61 | PDE5A (0.49) | SMN1; SMN2ALDH1A1HTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044011-A1 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | MEREK PATENT GMBH (DE) | 2004-03-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044011-A1 | 2-Aminoalkyl-thieno[2,3-d]pyrimidines | DPYD, PDE3A, PDE2A | SMN1; SMN2 2219/4885ALDH1A1 125/4885HTT 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.